ESC 365 - Combined ARNI and SGLT2i impacts on peak tricuspid regurgitant velocity and echocardiographic probability of pulmonary hypertension

ESC Professional Premium Access

Combined ARNI and SGLT2i impacts on peak tricuspid regurgitant velocity and echocardiographic probability of pulmonary hypertension

Session: Current pharmacological treatments for pulmonary hypertension

Topic: Pharmacotherapy

Speaker: Doctor M. Stracqualursi (Milan, IT)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Marco Stracqualursi

University of Milan, Milan (Italy)

0 follower

8 more presentations in this session

Effects of beta blockers on outcome in patients with PAH with and without comorbid conditions: a Multicenter Prospective Cohort Study (BNP-PL).

Speaker: Doctor M. Waligora (Krakow, PL)

The safety and efficacy of treprostinil for the treatment of pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials

Speaker: Mr H. Khasawneh (Irbid, JO)

Efficacy and tolerability of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : insights from a single-centre study

Speaker: Doctor H. Tokgoz (Istanbul, TR)

Metoprolol therapy in patients with Eisenmenger syndrome (MINES) study. A single-centre, double-blinded, randomised, placebo-controlled trial

Speaker: Doctor A. Pius (New Delhi, IN)

Efficacy of specific drug class therapy in pulmonary arterial hypertension associated with HIV, portal hypertension or both: a single Center experience

Speaker: Doctor F. Cennerazzo (Bologna, IT)

Access the full session

Current pharmacological treatments for pulmonary hypertension

Speakers: Doctor M. Stracqualursi, Doctor M. Waligora, Mr H. Khasawneh, Doctor H. Tokgoz, Doctor A. Pius...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources